Dr. Cord Dohrmann
Gastroenterology
Eternygen GmbH
Germany
Biography
Since March 2016 CEO of Topas Therapeutics GmbH which was spun-out of Evotec AG and financed by a strong strategic syndicate of Epidarex Capital, EMBL Ventures, Gimv and Evotec AG. From 2014-2016 Executive Vice President Business Development EVT Innovate of Evotec AG (Hamburg, Oxford). From 2006-2014 Managing Director of Bionamics plc, an asset management company set up to identify, develop and commercialize innovative projects in the Life Science arena, e.g. the NEU² consortium focusing on neurological diseases, especially Multiple Sclerosis. In 2014 Evotec acquired Bionamics GmbH From 1997-2004 Chief Scientific Officer of the listed biotech company Evotec AG (Hamburg, Oxford), a technology and service provider to the pharmaceutical industry. Before that 6 years in the pharmaceutical industry (Sanofi Aventis) in preclinical research and alliance management. He studied chemistry and biochemistry and received his education and scientific career in Kiel, Munich, Cambridge/UK and Boston/US.
Research Interest
Since March 2016 CEO of Topas Therapeutics GmbH which was spun-out of Evotec AG and financed by a strong strategic syndicate of Epidarex Capital, EMBL Ventures, Gimv and Evotec AG. From 2014-2016 Executive Vice President Business Development EVT Innovate of Evotec AG (Hamburg, Oxford). From 2006-2014 Managing Director of Bionamics plc, an asset management company set up to identify, develop and commercialize innovative projects in the Life Science arena, e.g. the NEU² consortium focusing on neurological diseases, especially Multiple Sclerosis. In 2014 Evotec acquired Bionamics GmbH From 1997-2004 Chief Scientific Officer of the listed biotech company Evotec AG (Hamburg, Oxford), a technology and service provider to the pharmaceutical industry. Before that 6 years in the pharmaceutical industry (Sanofi Aventis) in preclinical research and alliance management. He studied chemistry and biochemistry and received his education and scientific career in Kiel, Munich, Cambridge/UK and Boston/US.
